According to their patient data, EAF2 and PTEN are downregulated concurrently in >50% of advanced human prostate cancer (Gleason scores of 8–9) specimens, indicating that EAF2 and PTEN co-downregulation represents poor prognosis (Ai et al., 2014). This evidence concerns the gene PTEN and prostate carcinoma.